Published in J Clin Invest on December 10, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood (2013) 1.73
The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet (2015) 1.61
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60
Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. Cancer Cell (2014) 1.57
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov (2013) 1.13
Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood (2014) 1.05
Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest (2014) 0.99
RAS diseases in children. Haematologica (2014) 0.95
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther (2013) 0.95
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica (2015) 0.94
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. J Clin Invest (2014) 0.94
Emerging EPO and EPO receptor regulators and signal transducers. Blood (2015) 0.93
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front Pediatr (2014) 0.92
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer (2015) 0.91
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum Mol Genet (2013) 0.87
Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro Oncol (2014) 0.87
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov (2014) 0.86
NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis. Blood (2014) 0.83
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia (2016) 0.82
Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Hum Mol Genet (2013) 0.81
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res (2016) 0.81
Acquired expression of Cbl(Q367P) in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia. Blood (2017) 0.80
NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Genes Dev (2014) 0.79
Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Am J Pathol (2013) 0.78
Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica (2015) 0.78
KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nat Commun (2016) 0.77
The role of nerve microenvironment for neurofibroma development. Oncotarget (2016) 0.75
Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast. Oncologist (2016) 0.75
Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Front Oncol (2016) 0.75
Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J Clin Invest (2016) 0.75
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica (2016) 0.75
Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo. Circulation (2013) 0.75
Ginsenoside Rg1 improves bone marrow haematopoietic activity via extramedullary haematopoiesis of the spleen. J Cell Mol Med (2015) 0.75
Stem cells: Dual response to Ras mutation. Nature (2013) 0.75
Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem (2017) 0.75
GATA Factor-Regulated Samd14 Enhancer Confers Red Blood Cell Regeneration and Survival in Severe Anemia. Dev Cell (2017) 0.75
Translational hematology. Wien Med Wochenschr (2014) 0.75
RAS Proteins and Their Regulators in Human Disease. Cell (2017) 0.75
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature (2000) 16.75
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell (2007) 5.28
Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood (2003) 4.91
Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev (2001) 4.68
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet (1996) 3.08
Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med (1997) 3.04
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett (2008) 2.28
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol (2006) 1.71
Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol (2011) 1.70
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell (2004) 1.52
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood (2007) 3.11
Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell (2008) 2.67
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42
JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell (2009) 2.41
New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell (2006) 2.34
Comparative transcriptional profiling of two contrasting rice genotypes under salinity stress during the vegetative growth stage. Plant Physiol (2005) 2.28
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood (2006) 1.93
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc (2007) 1.89
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood (2013) 1.85
Detecting single-feature polymorphisms using oligonucleotide arrays and robustified projection pursuit. Bioinformatics (2005) 1.79
Definitive hematopoietic stem/progenitor cells manifest distinct differentiation output in the zebrafish VDA and PBI. Development (2009) 1.79
Migratory path of definitive hematopoietic stem/progenitor cells during zebrafish development. Blood (2007) 1.74
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem (2006) 1.68
Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol (2009) 1.67
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
Influenza H7N9 and H9N2 viruses: coexistence in poultry linked to human H7N9 infection and genome characteristics. J Virol (2014) 1.67
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. J Surg Res (2011) 1.61
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood (2010) 1.60
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med (2003) 1.60
A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine (2002) 1.56
Factors contributing to high costs and inequality in China's health care system. JAMA (2007) 1.55
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer (2006) 1.54
Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis. Cell Transplant (2010) 1.48
Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev (2007) 1.48
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc (2007) 1.42
Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol (2007) 1.41
Use of a donor heart with symptomatic WPW in an alternate donor program. J Heart Lung Transplant (2002) 1.39
HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J Biol Chem (2008) 1.38
Does cochlear implantation and electrical stimulation affect residual hair cells and spiral ganglion neurons? Hear Res (2006) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood (2011) 1.36
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood (2006) 1.35
Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A (2009) 1.35
Comparison of round window and cochleostomy approaches with a prototype hearing preservation electrode. Audiol Neurootol (2006) 1.34
The draft genome of the carcinogenic human liver fluke Clonorchis sinensis. Genome Biol (2011) 1.34
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A (2003) 1.32
Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med (2011) 1.31
Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients. Am J Surg (2009) 1.31
Distinct functions for different scl isoforms in zebrafish primitive and definitive hematopoiesis. PLoS Biol (2007) 1.29
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (2003) 1.29
Irf8 regulates macrophage versus neutrophil fate during zebrafish primitive myelopoiesis. Blood (2010) 1.28
A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell (2005) 1.27
China's engagement with global health diplomacy: was SARS a watershed? PLoS Med (2010) 1.27
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut (2012) 1.22
Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol (2005) 1.20
Hospital-Based Surveillance of Rotavirus Diarrhea in the People's Republic of China, August 2003-July 2007. J Infect Dis (2009) 1.19
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19
A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer (2014) 1.15
Percutaneous epicardial mapping during ablation of difficult accessory pathways as an alternative to cardiac surgery. Heart Rhythm (2004) 1.15
Structural organization of the inactive X chromosome in the mouse. Nature (2016) 1.15
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov (2013) 1.13
Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J Hypertens (2010) 1.12
Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy. J Neurochem (2004) 1.12
A multichannel scala tympani electrode array incorporating a drug delivery system for chronic intracochlear infusion. Hear Res (2002) 1.11
Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun (2003) 1.11
The epidemiology and burden of rotavirus in China: a review of the literature from 1983 to 2005. Vaccine (2006) 1.11
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10
Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol (2014) 1.10
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood (2011) 1.08
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood (2005) 1.08
CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg (2013) 1.07
Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat (2008) 1.07
Targeting Ras in myeloid leukemias. Clin Cancer Res (2008) 1.07
Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. Exp Hematol (2002) 1.06
Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J Clin Endocrinol Metab (2012) 1.06
Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta (2010) 1.06
Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood (2006) 1.06
Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation. Hum Mol Genet (2008) 1.05
Cochlear implantation in rats: a new surgical approach. Hear Res (2005) 1.05
Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One (2012) 1.04
Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging (2014) 1.04
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med (2002) 1.04
Population analysis of the Fusarium graminearum species complex from wheat in China show a shift to more aggressive isolates. PLoS One (2012) 1.03
LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm (2009) 1.03
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03
The carcinogenic liver fluke, Clonorchis sinensis: new assembly, reannotation and analysis of the genome and characterization of tissue transcriptomes. PLoS One (2013) 1.02
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res (2007) 1.02
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med (2009) 1.02
De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02
Genome-wide misexpression of X-linked versus autosomal genes associated with hybrid male sterility. Genome Res (2010) 1.01